Okamoto 2014.

Methods	Study design: parallel RCT Duration of study: not reported Duration of follow‐up: 24 months
Participants	Country: Japan Setting: single centre Inclusion criteria: kidney transplant recipients with SCr ≤ 177µmol/L for at least 1 year Number: treatment group (5); control group (7) Mean age ± SD (years): treatment group (52.8 ± 12.6); control group (52.9 ± 7.3) Sex (M/F): treatment group (4/1); control group (4/3) Exclusion criteria: not reported
Interventions	Treatment group Alendronate (oral): 35 mg/week Control group No treatment Co‐interventions Not reported
Outcomes	Change in BMD of the whole body Changes in serum calcium, phosphate, whole PTH, and biomarkers of bone turnover Kidney function (eGFR)
Notes	Funding source: partially funded by Merck Sharpe Dohme K.K. Trial registration: JMA‐IIA00155 of JMACCT CTR
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unlikely to be blinded due to differences in treatments (oral treatment versus no treatment)
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Patient important outcomes not captured or reported systematically
Other bias	Unclear risk	Partially funded by Merck Sharpe Dohme K.K.